|
6
|
Wood LS, Conway D, Lapuente M, Salvador G, Fernandez Gomez S, Carroll Bullock A, Devgan G, Burns KD. Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses. JOURNAL OF INFUSION NURSING 2022; 45:142-153. [PMID: 35537002 PMCID: PMC9071022 DOI: 10.1097/nan.0000000000000465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance is now considered the standard-of-care treatment for patients with locally advanced or metastatic UC who responded or experienced disease stabilization after 1L platinum-containing chemotherapy, and it is the only category 1 preferred checkpoint inhibitor maintenance option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic UC. This article reviews key considerations related to avelumab 1L maintenance therapy that infusion nurses should be familiar with, including dosing, administration, and immune-related adverse event recognition and management, to ensure safe and appropriate use of this important and impactful therapy.
Collapse
Affiliation(s)
- Laura S. Wood
- Corresponding Author: Laura Wood, MSN, RN, OCN®, Cleveland Clinic Taussig Cancer Center, Cleveland, OH ()
| | - Dawn Conway
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - Maria Lapuente
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - George Salvador
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - Sheila Fernandez Gomez
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - Andrea Carroll Bullock
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - Geeta Devgan
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| | - Kathleen D. Burns
- Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns)
- Laura S. Wood, MSN, RN, OCN, is the renal cancer clinical research coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She completed both her bachelor's and master's degrees in nursing at Kent State University in Kent, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Ms Wood is a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board. She is also active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Ms Wood has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. She was also the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award
- Dawn Conway, BSN, RN, OCN, is a registered nurse with 14 years of oncology experience, the first 3 years of which were spent as a bone marrow transplant nurse at Mount Sinai in New York City. For the past 11 years, Ms Conway has been working with the genitourinary oncology group at University of Chicago Medicine, specifically with patients with urothelial cancer, making her an expert in urothelial cancer management
- Maria Lapuente, RN, works as the lead research nurse for the genitourinary team at St Bartholomew's Hospital in London, United Kingdom. She has 10 years of experience in oncology, including more than 4 years of cancer research collaboration with Dr Thomas Powles. She has specialized in immunotherapy treatments, particularly in phase 1 combination trials. Ms Lapuente has recently expanded her area of expertise into radiotherapy and chemotherapy in combination with immunotherapy trials for patients with metastatic nonsmall cell lung cancer. She is also the principal investigator for a questionnaire study exploring the assessment of the Managing Advanced Cancer Pain Together conversation tool to facilitate communication between patients and their health care professionals, involving patients with genitourinary, lung, breast, and myeloma cancer
- George Salvador, RGN, has 9 years of nursing experience and 6 years of experience in a hematology-oncology department. He is also part of the vascular team at St Bartholomew's Hospital that deals with peripheral and central lines, such as Hickman, Portacath, and peripherally inserted central catheters. Currently, Mr Salvador is pursuing his master's degree in advanced cancer care, which includes nurse prescribing
- Sheila Fernandez Gomez, RN, CNS, is a registered nurse with 8 years of experience in oncology, including more than 4 years working as a senior chemotherapy/oncology/hematology nurse at St Bartholomew's Hospital. She has recently been promoted to acute oncology clinical nurse specialist at St George's Hospital in London and has acquired a specialty in systemic anticancer therapy regimens. This experience, along with her qualifications, has given her the confidence to assess and manage acute oncology complications
- Andrea Carroll Bullock, BSN, ISMPP, CMPP, is the director of US medical communications at EMD Serono, where she has directed US medical publications and communications in the oncology, neurology, immunology, fertility, and HIV therapeutic areas for the past 4 years. She has 20 years of experience in the pharmaceutical industry. Prior to joining industry, Ms Carroll Bullock worked as a registered nurse in teaching hospitals, such as the MedStar Washington Hospital Center. Her primary area of focus in the clinical setting was caring for patients in the medical intensive care and oncology units. Additionally, she has experience as a nurse manager for a community-based hematology/oncology practice, where she was responsible for treating patients and managing the infusion center. Ms Carroll Bullock holds a bachelor of science in nursing from Howard University and is a master of business administration candidate at Johns Hopkins Carey Business School
- Geeta Devgan, PhD, is a senior medical director in US medical affairs at Pfizer Oncology. She received her PhD in molecular, cellular, and developmental biology from Yale University and completed her postdoctoral training at Memorial Sloan-Kettering Cancer Center. Dr Devgan has more than 15 years of oncology experience in medical leadership roles within pharmaceutical companies
- Kathleen D. Burns, MSN, RN, AGACNP-BC, OCN, has a postmaster's certificate for nurse practitioners in acute care–gerontology from the University of Connecticut. Her work experience includes 28 years of cancer nursing in patient care, education, and management
| |
Collapse
|
|
10
|
Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, Loriot Y, Sridhar SS, Tsuchiya N, Kopyltsov E, Sternberg CN, Bellmunt J, Aragon-Ching JB, Petrylak DP, Laliberte R, Wang J, Huang B, Davis C, Fowst C, Costa N, Blake-Haskins JA, di Pietro A, Grivas P. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2020; 383:1218-1230. [PMID: 32945632 DOI: 10.1056/nejmoa2002788] [Citation(s) in RCA: 910] [Impact Index Per Article: 182.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progression-free survival and safety. RESULTS Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.86; P = 0.001). Avelumab also significantly prolonged overall survival in the PD-L1-positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% CI, 0.40 to 0.79; P<0.001). The median progression-free survival was 3.7 months in the avelumab group and 2.0 months in the control group in the overall population (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75) and 5.7 months and 2.1 months, respectively, in the PD-L1-positive population (hazard ratio, 0.56; 95% CI, 0.43 to 0.73). The incidence of adverse events from any cause was 98.0% in the avelumab group and 77.7% in the control group; the incidence of adverse events of grade 3 or higher was 47.4% and 25.2%, respectively. CONCLUSIONS Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.).
Collapse
Affiliation(s)
- Thomas Powles
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Se Hoon Park
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Eric Voog
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Claudia Caserta
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Begoña P Valderrama
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Howard Gurney
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Haralabos Kalofonos
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Siniša Radulović
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Wim Demey
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Anders Ullén
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Yohann Loriot
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Srikala S Sridhar
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Norihiko Tsuchiya
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Evgeny Kopyltsov
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Cora N Sternberg
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Joaquim Bellmunt
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Jeanny B Aragon-Ching
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Daniel P Petrylak
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Robert Laliberte
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Jing Wang
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Bo Huang
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Craig Davis
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Camilla Fowst
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Nuno Costa
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - John A Blake-Haskins
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Alessandra di Pietro
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| | - Petros Grivas
- From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.)
| |
Collapse
|